Clinical Trials Directory

Trials / Completed

CompletedNCT00348400

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
Innovative Medical · Industry
Sex
All
Age
18 Years
Healthy volunteers

Summary

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

Conditions

Interventions

TypeNameDescription
DRUGBrimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost

Timeline

First posted
2006-07-04
Last updated
2007-06-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00348400. Inclusion in this directory is not an endorsement.